Advances in the diagnosis and treatment of neuroblastoma
暂无分享,去创建一个
[1] A. Davidoff,et al. Humoral response to vaccination with interleukin-2-expressing allogeneic neuroblastoma cells after primary therapy. , 2000, Medical and pediatric oncology.
[2] W. London,et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] G. Melino,et al. Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma. , 2000, Experimental cell research.
[4] D. Neuberg,et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. , 2000, Human gene therapy.
[6] D. Stram,et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Look,et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study. , 2000, Journal of pediatric hematology/oncology.
[8] A. Eggert,et al. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] D. Stram,et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] D. Stram,et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Groshen,et al. Integrins αvβ3 and αvβ5 Are Expressed by Endothelium of High-Risk Neuroblastoma and Their Inhibition Is Associated with Increased Endogenous Ceramide , 2000 .
[12] D. Frappaz,et al. LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Rademaker,et al. Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] D. Stram,et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas , 1999, Oncogene.
[15] K K Matthay,et al. The International Neuroblastoma Pathology Classification (the Shimada system) , 1999, Cancer.
[16] K K Matthay,et al. Molecular biology of neuroblastoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] F. Speleman,et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. , 1999, The New England journal of medicine.
[18] S. Cohn,et al. Long-term outcome of patients with intraspinal neuroblastoma. , 1999, Medical and pediatric oncology.
[19] S. Jhanwar,et al. Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] P. Haber,et al. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] W. Gerald,et al. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] M. Bernstein,et al. Topotecan in Pediatric Patients With Recurrent and Progressive Solid Tumors: A Pediatric Oncology Group Phase II Study , 1998, Journal of pediatric hematology/oncology.
[23] A. Look,et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Uttenreuther-Fischer,et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Stram,et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R. Hanada,et al. Spontaneous regression of localized neuroblastoma detected by mass screening. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] D. Frappaz,et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] D. Bigner,et al. Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors , 1997, The Journal of experimental medicine.
[29] B. Gallie,et al. MYCN protein expression as a predictor of neuroblastoma prognosis. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] E. Halperin,et al. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. , 1997, European journal of cancer.
[31] T. Klingebiel,et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. , 1997, European journal of cancer.
[32] F. Berthold,et al. The international neuroblastoma risk groups (INRG): a preliminary report , 1997 .
[33] L. Robison,et al. Infant Cancer in the U.S.: Histology‐Specific Incidence and Trends, 1973 to 1992 , 1997, Journal of pediatric hematology/oncology.
[34] M. Slim,et al. Prenatally diagnosed neuroblastoma , 1997, Cancer.
[35] K. Matthay,et al. A Phase I/IB trial of murine monoclonal anti‐GD2 antibody 14.G2a plus interleukin‐2 in children with refractory neuroblastoma , 1997, Cancer.
[36] M. Cohen,et al. CD44 expression in neuroblastoma and related tumors. , 1997, Journal of pediatric hematology/oncology.
[37] G. Mohapatra,et al. Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.
[38] S. Cohn,et al. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. , 1997, Medical and pediatric oncology.
[39] J. Krischer,et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] A. Look,et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. , 1997, Journal of the National Cancer Institute.
[41] O. Delattre,et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] S. Påhlman,et al. The Angiogenesis Inhibitor TNP-470 Reduces the Growth Rate of Human Neuroblastoma in Nude Rats , 1997, Pediatric Research.
[43] M. Ziegler,et al. TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. , 1997, Journal of pediatric surgery.
[44] J. García,et al. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study. , 1996, Medical and pediatric oncology.
[45] J. García,et al. Interleukin-2 in neuroblastoma: clinical perspectives based on biological studies. , 1996, Cancer biotherapy & radiopharmaceuticals.
[46] C. Dominici,et al. Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis. , 1996, British Journal of Cancer.
[47] T. Rebbeck,et al. Familial predisposition to neuroblastoma does not map to chromosome band 1p36. , 1996, Cancer research.
[48] J. Becker,et al. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[49] D. Frappaz,et al. The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease: A prospective study of 42 patients‐‐Results of the NBL 90 study of the French Society of Pediatric Oncology , 1996, Cancer.
[50] W. Gerald,et al. International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] A. Rademaker,et al. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] W. Gerald,et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] S. Cohn,et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. , 1996, The New England journal of medicine.
[54] Rogier Versteeg,et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. , 1996, The New England journal of medicine.
[55] A. Nakagawara,et al. Expression of TrkC in favorable human neuroblastomas. , 1996, Oncogene.
[56] F. Berthold,et al. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. , 1995, Cancer research.
[57] A. Look,et al. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. , 1995, Cancer research.
[58] D. Stram,et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. , 1995, Journal of the National Cancer Institute.
[59] P. D. de Alarcon,et al. Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G. , 1995, The Journal of pediatrics.
[60] R. Hanada,et al. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] K. Matthay,et al. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] A. Look,et al. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. , 1995, Cancer research.
[63] D. Stram,et al. Surgical management and outcome of locoregional neuroblastoma: comparison of the Childrens Cancer Group and the international staging systems. , 1995, Journal of pediatric surgery.
[64] W. Gerald,et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] J. Shuster,et al. The Pediatric Oncology Group experience with the international staging system criteria for neuroblastoma. Member Institutions of the Pediatric Oncology Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] S. Cohn,et al. Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. , 1994, The Journal of pediatrics.
[67] N. Gross,et al. Altered growth and phenotype in clonal mycN transfectants of the sk‐n‐sh neuroblastoma cell line , 1994, International journal of cancer.
[68] C. Manohar,et al. The biological effects of antisense N-myc expression in human neuroblastoma. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[69] A. Nakagawara,et al. Expression and function of TRK-B and BDNF in human neuroblastomas , 1994, Molecular and cellular biology.
[70] J. Schiller,et al. Activation of multiple effector mechanisms to enhance tumor immunotherapy. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[71] D. Stram,et al. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] J. Estroff,et al. Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children's Hospital. , 1993, Pediatrics.
[73] F. Berthold,et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.
[74] C. Dominici,et al. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. , 1993, Cancer research.
[75] A. Cantor,et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. , 1993, The New England journal of medicine.
[76] D. Stram,et al. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. , 1993, Journal of the National Cancer Institute.
[77] R. Reisfeld,et al. A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. , 1993, Cancer research.
[78] M. Nishi,et al. Mass screening of neuroblastoma in Sapporo City, Japan. , 1992, The American journal of pediatric hematology/oncology.
[79] C. Raffel. Spinal cord compression by epidural tumors in childhood. , 1992, Neurosurgery clinics of North America.
[80] J. Shuster,et al. Serum Lactate Dehydrogenase in Childhood Neuroblastoma A Pediatric Oncology Group Recursive Partitioning Study , 1992, American journal of clinical oncology.
[81] N. Berger,et al. Reassessment of patient response to monoclonal antibody 3F8. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] M. Arima,et al. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. , 1992, Cancer research.
[83] S. Ferrari,et al. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[84] T. Yokoyama,et al. Immunohistochemical analysis of N-myc protein expression in neuroblastoma: correlation with prognosis of patients. , 1991, Journal of pediatric surgery.
[85] J. Zucker,et al. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] R. Hoover,et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. , 1991, Cancer research.
[87] G. Heller,et al. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] A T Look,et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] J. Silber,et al. Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology. , 1991, Cancer research.
[90] M. LaQuaglia,et al. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] Y. Kaneko,et al. Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: a chromosome and N-myc amplification study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] M. Schwab,et al. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. , 1990, Cancer research.
[93] J. Locker,et al. A comparative analysis of nuclear DNA content and N‐myc gene amplification in neuroblastoma , 1990, Cancer.
[94] A. Rademaker,et al. Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma. , 1990, The American journal of pathology.
[95] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[96] M. Favrot,et al. A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 cases. , 1989, Cancer treatment reviews.
[97] N C Dracopoli,et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[98] K. Matthay,et al. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] P. Waber,et al. N-myc oncogene RNA expression in neuroblastoma. , 1988, Journal of the National Cancer Institute.
[100] C. R. Pinkerton,et al. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. , 1988, Progress in clinical and biological research.
[101] K. Matthay,et al. Complete pathologic maturation and regression of stage ivs neuroblastoma without treatment , 1988, Cancer.
[102] J. Shuster,et al. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] D. Munn,et al. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. , 1987, Cancer research.
[104] K. Propert,et al. Prognostic factors in neuroblastoma , 1987 .
[105] T. Gansler,et al. Flow cytometric DNA analysis of neuroblastoma. Correlation with histology and clinical outcome , 1986, Cancer.
[106] B. Kushner,et al. Familial neuroblastoma. Case reports, literature review, and etiologic considerations , 1986, Cancer.
[107] H. Sather,et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.
[108] T. Sawada,et al. MASS SCREENING FOR NEUROBLASTOMA IN INFANTS IN JAPAN Interim Report of a Mass Screening Study Group , 1984, The Lancet.
[109] H. B. Marsden,et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. , 1984, Journal of the National Cancer Institute.
[110] A. Look,et al. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. , 1984, The New England journal of medicine.
[111] T. Matsumura,et al. Neuroblastoma. Mass screening for early detection and its prognosis , 1984, Cancer.
[112] H. Varmus,et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.
[113] A. Ruusala,et al. Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation. , 1984, Cell differentiation.
[114] A. Green,et al. Chemotherapy as an alternative to laminectomy and radiation in the management of epidural tumor. , 1984, The Journal of pediatrics.
[115] N. Sidell,et al. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. , 1982, Journal of the National Cancer Institute.
[116] A. Evans,et al. Serum ferritin as a guide to therapy in neuroblastoma. , 1980, Cancer research.
[117] J. Hutter,et al. Opsomyoclonus and Neuroblastoma , 1979, Clinical pediatrics.
[118] N. Jaffe,et al. Prognosis for children with neuroblastoma presenting with paralysis. , 1977, Journal of pediatric surgery.
[119] A. Evans,et al. Spontaneous regression of neuroblastoma. , 1976, National Cancer Institute monograph.
[120] D. King,et al. Dumbbell neuroblastomas in children. , 1975, Archives of surgery.
[121] N. Breslow,et al. Statistical estimation of prognosis for children with neuroblastoma. , 1971, Cancer research.
[122] C E Koop,et al. Special pattern of widespread neuroblastoma with a favourable prognosis. , 1971, Lancet.
[123] A. Evans,et al. A proposed staging for children with neuroblastoma. Children's cancer study group A , 1971, Cancer.
[124] D. Stram,et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[125] L. Ries,et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. , 1999 .
[126] K. Matthay,et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. , 1999, The New England journal of medicine.
[127] S. Lipshultz,et al. Anthracycline-induced cardiotoxicity in children and young adults. , 1998, Critical reviews in oncology/hematology.
[128] B. Hasegawa,et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[129] P. Bruzzi,et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[130] M. Kirpekar,et al. Spontaneous resolution of antenatally diagnosed adrenal masses. , 1996, Journal of pediatric surgery.
[131] D. Frappaz,et al. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[132] M. Barbacid. Neurotrophic Factors and Their Receptors , 1995, Bio/Technology.
[133] D. Frappaz,et al. Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors. , 1995, European journal of cancer.
[134] H. Jürgens,et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[135] G. Brodeur,et al. Prenatal detection of neuroblastoma by fetal ultrasonography. , 1994, The American journal of pediatric hematology/oncology.
[136] J. Murray,et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[137] C. Sainte-Rose,et al. Localized dumbbell neuroblastoma: a study of 25 cases treated between 1982 and 1987 using the same protocol. , 1993, Medical and pediatric oncology.
[138] C. Reynolds,et al. 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group. , 1992, Medical and pediatric oncology.
[139] J. Bourhis,et al. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. , 1991, Progress in clinical and biological research.
[140] R. Seeger,et al. Expression of GD2 ganglioside by untreated primary human neuroblastomas. , 1986, Cancer research.
[141] H. Sather,et al. Prognostic importance of serum neuron specific enolase in local and widespread neuroblastoma. , 1985, Progress in clinical and biological research.
[142] M. Israel,et al. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma , 1985, Nature.
[143] C. Pratt,et al. Metastatic epidural tumors in children. , 1982, Medical and pediatric oncology.
[144] B. Bernardi,et al. © 1999 Cancer Research Campaign Article no. bjoc.1999.0855 , 2022 .